A randomised, double-blind, active placebo-controlled, parallel groups, dose-response study of scopolamine hydrobromide (4–6 μg/kg) in patients with major depressive disorder

por Chen, Joseph C. C., Sumner, Rachael L., Krishnamurthy Naga, Venkat, Hoeh, Nicholas, Ayeni, Hafis Adetokunbo, Singh, Vikrant, Sundram, Frederick, Campbell, Douglas, Muthukumaraswamy, Suresh
Publicado 2020